Consolidated Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|
| Research and development | ||||
| Compensation and benefits | $ 1,482,946 | $ 1,909,518 | $ 2,983,810 | $ 3,213,358 |
| Consultants and outside costs | 233,798 | 194,783 | 364,159 | 466,258 |
| Material manufacturing costs | 227,602 | 567,430 | 653,691 | 1,079,137 |
| Clinical trial costs | 581,988 | 0 | 1,561,754 | 0 |
| License costs | 407,605 | 0 | 1,178,505 | 0 |
| Facilities and other costs | 479,149 | 403,648 | 981,807 | 802,555 |
| Research and development | 3,413,088 | 3,075,379 | 7,723,726 | 5,561,308 |
| General and administrative | ||||
| Compensation and benefits | 1,672,494 | 1,285,052 | 3,467,921 | 2,151,953 |
| Professional fees | 213,399 | 139,865 | 436,993 | 286,016 |
| Investor relations | 133,705 | 87,428 | 193,576 | 155,535 |
| General and administrative | 318,272 | 301,520 | 645,872 | 558,115 |
| General and administrative | 2,337,870 | 1,813,865 | 4,744,362 | 3,151,619 |
| Total operating expenses | 5,750,958 | 4,889,244 | 12,468,088 | 8,712,927 |
| Loss from operations | (5,750,958) | (4,889,244) | (12,468,088) | (8,712,927) |
| Other income (expense) | ||||
| Interest income | 524 | 0 | 861 | 0 |
| Rent income | 31,838 | 0 | 63,676 | 0 |
| Interest expense | (147) | 0 | (147) | (1,595) |
| Derivative gains | 156 | 1,313 | 498 | 10,725 |
| Total other income | 32,371 | 1,313 | 64,888 | 9,130 |
| Net loss | $ (5,718,587) | $ (4,887,931) | $ (12,403,200) | $ (8,703,797) |
| Net loss per common share - basic and diluted | $ (0.11) | $ (0.12) | $ (0.23) | $ (0.23) |
| Weighted average number of common shares outstanding - basic and diluted | 53,762,358 | 40,788,241 | 53,327,558 | 38,091,406 |
| X | ||||||||||
- Definition Amount of compensation and benefits for general and administrative during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of compensation and benefits for research and development during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of Consultants and outside costs during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of Facilities and other costs during the reporting period. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Investor relations for the during period. No definition available.
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of medical supplies consumed, for example, but not limited to, bandages, syringes and drugs, for patient care. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs incurred in the production of goods for sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|